Key result
Senolytic therapy reduces doxorubicin-induced aortic pulse-wave velocity by ~18%.
Why the study?
Mechanisms underlying doxorubicin chemotherapy-induced aortic stiffening are incompletely understood.
Does senolytic therapy prevent doxorubicin-induced aortic stiffening in a mouse model?
Population
Young adult (4-6 month) p16-3MR mice
Comparison
Doxorubicin with GCV or ABT263 vs Doxorubicin alone or control
Design
Preclinical animal and ex vivo study
Authors
Loading...
Senolytics attenuated doxorubicin-induced aortic stiffening in mice; hypothesis-generating and requires human trials before any clinical consideration.
Does senolytic therapy prevent doxorubicin-induced aortic stiffening in a mouse model?
Absolute Event Rate: 348% vs 425%
p-value: p=<0.05
Senolytic therapy prevents doxorubicin-induced aortic stiffening in mice by targeting cellular senescence and glycation stress, offering a potential approach to mitigate cardiovascular toxicity in cancer survivors.
Venkatasubramanian et al. (2025) studied Doxorubicin chemotherapy-induced aortic stiffening. Ganciclovir (GCV) or ABT263 vs. Doxorubicin alone was evaluated on Aortic pulse-wave velocity (PWV) (p=<0.05). Senolytic therapy with ganciclovir or ABT263 prevented Doxorubicin-induced increases in aortic pulse-wave velocity (348±4 and 342±7 cm/sec vs 425±6 cm/sec with Doxo alone; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: